Meeting
2023 ASCO Annual Meeting
A phase 1, first-in-human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2-overexpressing solid tumors.
Authors
Yara Abdou
University of North Carolina at Chapel Hill, Chapel Hill, NC
Yara Abdou , Elizabeth Claire Dees , Joanne E. Mortimer , Paula R Pohlmann , Melissa Lynne Johnson , Richard T. Maziarz , Jennifer M. Specht , Yuan Yuan , Naoto T. Ueno , Mathew Angelos , Saar Gill , Amy Ronczka , Thomas Condamine , Daniel Cushing , Debora Barton , Michael Klichinsky , Ramona F. Swaby , Kim Anna Reiss
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Cellular Immmunotherapy
Clinical Trial Registration Number
NCT04660929
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS2666)
DOI
10.1200/JCO.2023.41.16_suppl.TPS2666
Abstract #
TPS2666
Poster Bd #
506b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors.
First Author: Jordi Rodon Ahnert
Poster
2022 ASCO Annual Meeting
A phase 1, first-in-human (FIH) study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors.
First Author: Kim Anna Reiss
Poster
2023 ASCO Annual Meeting
Uncovering mechanisms of response of pembrolizumab and lenvatinib for the treatment of platinum-resistant high grade serous ovarian cancer.
First Author: Jeffrey How
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase 1, first-in-human (FIH) study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in subjects with HER2 overexpressing solid tumors.
First Author: Kim Anna Reiss